Logo image of VERO

VENUS CONCEPT INC (VERO) Stock Fundamental Analysis

NASDAQ:VERO - Nasdaq - US92332W2044 - Common Stock - Currency: USD

0.3521  -0.01 (-1.84%)

After market: 0.34 -0.01 (-3.44%)

Fundamental Rating

1

Taking everything into account, VERO scores 1 out of 10 in our fundamental rating. VERO was compared to 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of VERO have multiple concerns. VERO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VERO had negative earnings in the past year.
VERO had a negative operating cash flow in the past year.
In the past 5 years VERO always reported negative net income.
In the past 5 years VERO always reported negative operating cash flow.
VERO Yearly Net Income VS EBIT VS OCF VS FCFVERO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

VERO has a worse Return On Assets (-69.38%) than 74.74% of its industry peers.
VERO has a worse Return On Equity (-496.11%) than 86.84% of its industry peers.
Industry RankSector Rank
ROA -69.38%
ROE -496.11%
ROIC N/A
ROA(3y)-29.74%
ROA(5y)-32.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VERO Yearly ROA, ROE, ROICVERO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

With a decent Gross Margin value of 67.68%, VERO is doing good in the industry, outperforming 74.21% of the companies in the same industry.
In the last couple of years the Gross Margin of VERO has grown nicely.
VERO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.21%
GM growth 5Y9.61%
VERO Yearly Profit, Operating, Gross MarginsVERO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

VERO does not have a ROIC to compare to the WACC, probably because it is not profitable.
VERO has more shares outstanding than it did 1 year ago.
VERO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VERO is higher compared to a year ago.
VERO Yearly Shares OutstandingVERO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
VERO Yearly Total Debt VS Total AssetsVERO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -5.77, we must say that VERO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.77, VERO is not doing good in the industry: 72.63% of the companies in the same industry are doing better.
A Debt/Equity ratio of 3.40 is on the high side and indicates that VERO has dependencies on debt financing.
VERO's Debt to Equity ratio of 3.40 is on the low side compared to the rest of the industry. VERO is outperformed by 86.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.4
Debt/FCF N/A
Altman-Z -5.77
ROIC/WACCN/A
WACC4.96%
VERO Yearly LT Debt VS Equity VS FCFVERO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

VERO has a Current Ratio of 1.86. This is a normal value and indicates that VERO is financially healthy and should not expect problems in meeting its short term obligations.
VERO has a worse Current ratio (1.86) than 68.95% of its industry peers.
A Quick Ratio of 1.18 indicates that VERO should not have too much problems paying its short term obligations.
VERO's Quick ratio of 1.18 is on the low side compared to the rest of the industry. VERO is outperformed by 66.84% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.18
VERO Yearly Current Assets VS Current LiabilitesVERO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for VERO have decreased strongly by -15.56% in the last year.
The Revenue for VERO has decreased by -18.57% in the past year. This is quite bad
Measured over the past years, VERO shows a very strong growth in Revenue. The Revenue has been growing by 28.26% on average per year.
EPS 1Y (TTM)-15.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.95%
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-0.71%
Revenue growth 5Y28.26%
Sales Q2Q%-14.81%

3.2 Future

The Earnings Per Share is expected to grow by 21.42% on average over the next years. This is a very strong growth
Based on estimates for the next years, VERO will show a decrease in Revenue. The Revenue will decrease by -2.59% on average per year.
EPS Next Y-1.6%
EPS Next 2Y28.8%
EPS Next 3Y21.42%
EPS Next 5YN/A
Revenue Next Year-17.86%
Revenue Next 2Y-7.4%
Revenue Next 3Y-2.59%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
VERO Yearly Revenue VS EstimatesVERO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
VERO Yearly EPS VS EstimatesVERO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERO Price Earnings VS Forward Price EarningsVERO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERO Per share dataVERO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

VERO's earnings are expected to grow with 21.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.8%
EPS Next 3Y21.42%

More info and screens

0

5. Dividend

5.1 Amount

VERO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VENUS CONCEPT INC

NASDAQ:VERO (1/30/2025, 8:00:01 PM)

After market: 0.34 -0.01 (-3.44%)

0.3521

-0.01 (-1.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners25.41%
Inst Owner Change0%
Ins Owners2.55%
Ins Owner Change0%
Market Cap2.56M
Analysts47.5
Price TargetN/A
Short Float %0.83%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-56.48%
Min EPS beat(2)-108.38%
Max EPS beat(2)-4.58%
EPS beat(4)0
Avg EPS beat(4)-46.69%
Min EPS beat(4)-108.38%
Max EPS beat(4)-4.58%
EPS beat(8)2
Avg EPS beat(8)-20.68%
EPS beat(12)3
Avg EPS beat(12)-30.31%
EPS beat(16)4
Avg EPS beat(16)-25.37%
Revenue beat(2)0
Avg Revenue beat(2)-9.54%
Min Revenue beat(2)-14.85%
Max Revenue beat(2)-4.24%
Revenue beat(4)1
Avg Revenue beat(4)-9.35%
Min Revenue beat(4)-20.82%
Max Revenue beat(4)2.5%
Revenue beat(8)3
Avg Revenue beat(8)-4.34%
Revenue beat(12)4
Avg Revenue beat(12)-4.56%
Revenue beat(16)6
Avg Revenue beat(16)-3.48%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.33%
EPS NY rev (1m)0%
EPS NY rev (3m)1.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.8%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.25
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-8.02
EYN/A
EPS(NY)-2.34
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS9.26
BVpS1.39
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.38%
ROE -496.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.68%
FCFM N/A
ROA(3y)-29.74%
ROA(5y)-32.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.21%
GM growth 5Y9.61%
F-Score3
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 3.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.73%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.18
Altman-Z -5.77
F-Score3
WACC4.96%
ROIC/WACCN/A
Cap/Depr(3y)6.99%
Cap/Depr(5y)16.38%
Cap/Sales(3y)0.33%
Cap/Sales(5y)0.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.95%
EPS Next Y-1.6%
EPS Next 2Y28.8%
EPS Next 3Y21.42%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-0.71%
Revenue growth 5Y28.26%
Sales Q2Q%-14.81%
Revenue Next Year-17.86%
Revenue Next 2Y-7.4%
Revenue Next 3Y-2.59%
Revenue Next 5YN/A
EBIT growth 1Y4.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.88%
EBIT Next 3Y24.68%
EBIT Next 5YN/A
FCF growth 1Y67.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.51%
OCF growth 3YN/A
OCF growth 5YN/A